Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany-Reference-Cited by-同舟云学术

Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012/13 in Germany

Published:2018-01 Issue:4 Volume:36 Page:572-577
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Weinberger Raphael,von Kries Rüdiger,van der Linden Mark,Rieck Thorsten^ORCID,Siedler Anette,Falkenhorst Gerhard

Funder

Pfizer Pharma

German Ministry of Health

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference21 articles.

1. Centers for Disease Control and Prevention CDC. Progress in introduction of pneumococcal conjugate vaccine-worldwide. 2000–2012, MMWR. Morbidity and mortality weekly report (2013); 62(16):308.

2. Pneumococcal serotype evolution in Western Europe;Htar;BMC Infect. Dis.,2015

3. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance;Moore;The Lancet Infect. Dis.,2015

4. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis;Balsells;PloS one,2017

5. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study;Waight;The Lancet Infect. Dis.,2015

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Routine Childhood Immunization with 20-Valent versus 15-Valent Pneumococcal Conjugate Vaccines in Germany;Vaccines;2024-09-12

2. Nasopharyngeal carriage of Streptococcus pneumoniae among children aged 30 days to <60 months in Beijing and Shenzhen, China (2018–2021) during pneumococcal conjugate vaccine introduction and the coronavirus disease (COVID-19) pandemic;Frontiers in Pediatrics;2024-09-03

3. Long-term effect of pneumococcal conjugate vaccines on invasive pneumococcal disease incidence among people of all ages from national, active, laboratory-based surveillance in South Africa, 2005–19: a cohort observational study;The Lancet Global Health;2024-09

4. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population: A German Societal Perspective Analysis;Infectious Diseases and Therapy;2024-05-11

5. Cost-effectiveness of PCV20 to Prevent Pneumococcal Disease in the Pediatric Population - A German Societal Perspective Analysis;2024-03-15